Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO

Open label, single arm, multicenter phase II trial.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Lymphoid Leukemia
• Intervention / Treatment: Drug: Venetoclax

Detailed Description

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.

PREVENE (PREemptive VENEtoclax) trial.

• Study Type: Interventional
• Enrollment (Estimated): 82
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • CHU Amiens
  • Angers, France, 49933
    • CHU Angers
  • Annecy, France, 74374
    • CH Annecy
  • Bayonne, France, 64109
    • CH Côte Basque
  • Besançon, France, 25000
    • Hopitaljean Minjoz
  • Blois, France, 41000
    • CH Blois
  • Bordeaux, France, 33076
    • Institut Bergonie
  • Béziers, France, 34500
    • Ch Beziers
  • Caen, France, 14033
    • CHU Caen
  • Cesson-Sévigné, France, 35510
    • Hôpital privé Sévigné
  • Clermont-Ferrand, France, 63000
    • CHU Estaing
  • Créteil, France, 94000
    • CHU CRETEIL
  • Grenoble, France, 38043
    • CHU Grenoble
  • La Roche-sur-Yon, France, 85925
    • CHD Vendee
  • Le Mans, France, 72000
    • Chd Le Mans
  • Lille, France, 59037
    • Hôpital Huriez
  • Lyon, France, 69008
    • Centre Leon Berard
  • Marseille, France, 130009
    • Institut Paoli Calmette
  • Metz, France, 57085
    • Centre Hospitalier Regional Metz Thionville
  • Pessac, France, 33604
    • Bordeaux Pessac
  • Pierre-Bénite, France, 69495
    • Centre Hospitalier Lyon Sud
  • Rouen, France, 76038
    • Centre Henri Becquerel - Service Hématologie Clinique
  • Tours, France, 37044
    • Hôpital Bretonneau - Hématologie et Thérapie Cellulaire

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Established diagnosis of Chronic Lymphoid Leukemia by International Workshop Chronic Lymphoid Leukemia 2008 criteria with Matutes score Superior to 3, or Matutes score egal to 3 with CD200 positive and CD20 low
• High risk Binet stage A, patients presenting at least 2 from 3 risk factors: Lymphocytosis Superior to 13 Giga per liter, CD38 positive, beta2 microglobulin Superior to 2.5 milligram per liter.

Only patients with unmutated status will be treated and followed according to the trial.

• No prior chemotherapy, radiation or antibody treatment
• Age Superior to 18 years
• Life expectancy Superior to 6 months
• Performance status 0 to 2
• All parameters for risk stratification present
• Possibility of follow-up
• Adequate hepatic function per local laboratory reference range as follows: Aspartate transaminase and alanine transaminase Superior to 3.0 of upper limit of normal and Bilirubin inferior or egal to 1.5 of upper limit of normal (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
• Willingness to accept highly effective methods of contraception for the duration of therapy and 12 months thereafter
• Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at Screening.
• Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study

Exclusion Criteria:

• Binet Stage A patients with progressive disease according to International Workshop Chronic Lymphoid Leukemia 2008 criteria
• Clinically apparent autoimmune cytopenia, in particular antiglobulin test positive hemolytic anemia (positive antiglobulin test without anemia is not an exclusion criteria)
• Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Chronic Lymphoid Leukemia prior to the study
• Medical condition requiring the long term (estimated to be more than one month) use of oral corticosteroids
• Patient refusal to perform the bone marrow biopsy for evaluation points
• Patients with active bacterial, viral or fungal infection
• Subject is known to be positive for Human Immunodeficiency Virus
• Evidence of other clinically significant uncontrolled conditions
• Treatment with any other investigational agent or participating in another trial within 30 days prior to entering this study
• A female patient who is pregnant or breast feeding
• Concurrent severe diseases which exclude the administration of therapy
• Richter's syndrome
• Treatment with any of the following within 7 days prior to the first dose of study drug: Steroid therapy for anti-neoplastic intent, moderate or strong cytochrome P450 3A inhibitors, moderate or strong cytochrome P450 3A inducers
• Administration or consumption of any of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges, star fruit.
• Prior and concomitant therapy
• Malabsorption syndrome or other condition that precludes enteral route of administration
• Received a live viral vaccination within 6 months prior to the first dose of study drug. A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes
• Major surgery within 30 days prior to the first dose of study treatment
• History of prior other malignancy that could affect compliance with the protocol or interpretation of results
• Not affiliated to social security

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: ARM A VENETOCLAX; VENETOCLAX

Drug: Venetoclax; Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.; For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).; For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete response rate	according to International Workshop Chronic Lymphoid Leukemia 2008 guidelines and with Minimal Residual Disease inferior to 0.01 percent (as determined by 8-color technique) in bone marrow at month 12.	12 months

Collaborators and Investigators

• Sponsor: French Innovative Leukemia Organisation
• Investigators: Principal Investigator: Vincent LEVY, MD PD, French Innovative Leukemia Organisation; Study Chair: Luc-Matthieu FORNECKER, MD, French Innovative Leukemia Organisation

Publications and helpful links

Helpful Links

• French Innovative Leukemia Organization (FILO) internet site

Study record dates

Study Major Dates

• Study Start (Actual): May 22, 2019
• Primary Completion (Actual): January 1, 2022
• Study Completion (Estimated): April 24, 2030

Study Registration Dates

• First Submitted: December 5, 2018
• First Submitted That Met QC Criteria: December 5, 2018
• First Posted (Actual): December 6, 2018

Study Record Updates

• Last Update Posted (Actual): November 26, 2025
• Last Update Submitted That Met QC Criteria: November 21, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Leukemia, Lymphoid; Leukemia; Hemic and Lymphatic Diseases; Leukemia, B-Cell; Antineoplastic Agents; venetoclax
• Other Study ID Numbers: PREVENE FILOCLL10

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: eCRF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No